Patents by Inventor Nathalie Rolhion

Nathalie Rolhion has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antagonists for the prevention or treatment of inflammatory bowel disease, and more particularly of Crohn's disease
    Patent number: 8974789
    Abstract: An antagonist of the interaction between the Gp96 receptor and E. coli AIEC strains, for the prevention or treatment of inflammatory bowel disease. The antagonist is for specifically blocking or reducing the interaction between Gp96 receptor and the outer membrane vesicles (OMVs), typically the outer protein membrane OmpA of E. coli AIEC strains. The inventions provides for pharmaceutical compositions containing such an antagonist, which may be an antibody against gp96 or OmpA, or a gp96 or OmpA polypeptide. It may be combined to an antagonist of the interaction between the CEACAM6 receptor and E. coli AIEC strains, such as an anti-CEACAM6 antibody, a CEACAM6 polypeptide, or a mannoside or particle having a mannose unit. The invention also relates to a method for the diagnosis of inflammatory bowel disease, or of the determination of a predisposition of a person to develop inflammatory bowel disease.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: March 10, 2015
    Assignee: Universite d'Auvergne Clermont I
    Inventors: Arlette Darfeuille-Michaud, Paul Hofman, Nathalie Rolhion
  • Antagonists for the Prevention of Treatment of Inflammatory Bowel Disease, and More Particularly of Crohn's Disease
    Publication number: 20130084292
    Abstract: An antagonist of the interaction between the Gp96 receptor and E. coli AIEC strains, for the prevention or treatment of inflammatory bowel disease. The antagonist is for specifically blocking or reducing the interaction between Gp96 receptor and the outer membrane vesicles (OMVs), typically the outer protein membrane OmpA of E. coli AIEC strains. The inventions provides for pharmaceutical compositions containing such an antagonist, which may be an antibody against gp96 or OmpA, or a gp96 or OmpA polypeptide. It may be combined to an antagonist of the interaction between the CEACAM6 receptor and E. coli AIEC strains, such as an anti-CEACAM6 antibody, a CEACAM6 polypeptide, or a mannoside or particle having a mannose unit. The invention also relates to a method for the diagnosis of inflammatory bowel disease, or of the determination of a predisposition of a person to develop inflammatory bowel disease.
    Type: Application
    Filed: April 15, 2011
    Publication date: April 4, 2013
    Applicant: UNIVERSITE D'AUVERGNE CLERMONT I
    Inventors: Arlette Darfeuille-Michaud, Paul Hofman, Nathalie Rolhion